NCT02283502

Brief Summary

The objectives of this program are to verify the safety and effectiveness of the MRgHIFU system developed by the division of Medical Engineering of National Health Research Institutes (NHRI)

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Sep 2014

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 28, 2014

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 5, 2014

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

November 5, 2014

Status Verified

October 1, 2014

Enrollment Period

8 months

First QC Date

October 28, 2014

Last Update Submit

November 2, 2014

Conditions

Keywords

Uterine fibroidmagnetic resonance imagingultrasoundnon-invasive therapy

Outcome Measures

Primary Outcomes (1)

  • Check Adverse Event or Serious Adverse Event

    follow up

    six month

Secondary Outcomes (2)

  • Using MRI to confirm the volume of the fibromyoma.

    Screen, after treatment 1Month, 3Month, 6Month

  • Using quality of life questionnaire to compare quality of life that before and after treatment

    Screen, after treatment 1Month, 3Month, 6Month

Study Arms (1)

Intervention: MRgHIFU, Surgery

EXPERIMENTAL

Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids

Device: MRgHIFU system

Interventions

Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids

Intervention: MRgHIFU, Surgery

Eligibility Criteria

Age35 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Already sign in the Informed Consent Form。
  • The woman who want to operate the Hysteromyomectomy, and the volume of the fibromyoma is between 5-10 cm, will be included。
  • Woman age between 35\~45 years, and do not want to be pregnant
  • Abdominal circumference≦95 ㎝.
  • No pregnant.
  • MRI compatible.

You may not qualify if:

  • Pregnant or Breast-feeding.
  • MRI uncompatible.
  • Woman who has scar in Abdomen.
  • Immunodeficiency or cancer.
  • Use the clinical medicine before 3 month age.
  • The woman who will not follow the project. -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Trial Center

Taoyuan District, Taiwan, 333, Taiwan

RECRUITING

MeSH Terms

Conditions

Leiomyoma

Condition Hierarchy (Ancestors)

Neoplasms, Muscle TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasms

Study Officials

  • Chin-Jung Wang, MD

    Chang Gung Memorial Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chin-Jung Wang, MD

CONTACT

Ho Yun Li, Master

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor, MD

Study Record Dates

First Submitted

October 28, 2014

First Posted

November 5, 2014

Study Start

September 1, 2014

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

November 5, 2014

Record last verified: 2014-10

Locations